Dual inhibition of BRAF and mTOR in BRAF V600E -mutant pediatric, adolescent, and young adult brain tumors
Molecular Case Studies · 2020-08 · 6 (4) · a005041
DOI: 10.1101/mcs.a005041 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Molecular Case Studies, online erschienen am 25.08.2020. Verfasst von Shiraj Sen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Sarah Cannon Research Institute at HealthONE, Denver, Colorado 80218, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Although BRAF inhibition has demonstrated activity in BRAF V600 –mutated brain tumors, ultimately these cancers grow resistant to BRAF inhibitor monotherapy. Parallel activation of the phosphatidylinositol 3-kinase-mammalian target of rapamycin pathway has been implicated as a mechanism of primary and secondary resistance to BRAF inhibition. Moreover, it has been shown specifically that mTOR signaling activation occurs in BRAF-mutant brain tumors. We therefore conducted phase 1 trials combining vemurafenib with everolimus, enrolling five pediatric and young adults with BRAF V600 -mutated brain tumors. None of the patients required treatment discontinuation as a result of adverse events. Overall, two patients (40%) had a partial response and one (20%) had 12 mo of stable disease as best response. Co-targeting BRAF and mTOR in molecularly selected brain cancers should be further investigated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sarah Cannon Research Institute at HealthONE, Denver, Colorado 80218, USA.
- Pediatrics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
- Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
- Neuro-oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
- Diagnostic Radiology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
- Department of Melanoma Medical Oncology and Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
ORCID-Profile: Vivek Subbiah
Förderung
- NCI NIH HHS
- NCATS NIH HHS
Zitieren
APA
Sen, S., Tanaka, R., Khatua, S., Zaky, W., Janku, F., Penas-Prado, M., Weathers, S. P., Behrang, A., Roszik, J., & Subbiah, V. (2020). Dual inhibition of BRAF and mTOR in BRAF V600E -mutant pediatric, adolescent, and young adult brain tumors. Molecular Case Studies, 6(4), a005041. https://doi.org/10.1101/mcs.a005041
Vancouver
Sen S, Tanaka R, Khatua S, Zaky W, Janku F, Penas-Prado M, et al. Dual inhibition of BRAF and mTOR in BRAF V600E -mutant pediatric, adolescent, and young adult brain tumors. Molecular Case Studies. 2020;6(4):a005041. doi:10.1101/mcs.a005041
BibTeX
@article{Sen2020,
author = {Sen, Shiraj and Tanaka, Ryuma and Khatua, Soumen and Zaky, Wafik and Janku, Filip and Penas-Prado, Marta and Weathers, Shiao-Pei and Behrang, Amini and Roszik, Jason and Subbiah, Vivek},
title = {Dual inhibition of BRAF and mTOR in BRAF V600E -mutant pediatric, adolescent, and young adult brain tumors},
journal = {Molecular Case Studies},
year = {2020},
volume = {6},
number = {4},
pages = {a005041},
doi = {10.1101/mcs.a005041}
}
EUVIMED